149 related articles for article (PubMed ID: 12096004)
1. Activity of cefditoren against respiratory pathogens.
Clark CL; Nagai K; Dewasse BE; Pankuch GA; Ednie LM; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2002 Jul; 50(1):33-41. PubMed ID: 12096004
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
Seral C; Suárez L; Rubio-Calvo C; Gómez-Lus R; Gimeno M; Coronel P; Durán E; Becerril R; Oca M; Castillo FJ
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):210-5. PubMed ID: 18715733
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
[TBL] [Abstract][Full Text] [Related]
4. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
Peric M; Browne FA; Jacobs MR; Appelbaum PC
Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
[TBL] [Abstract][Full Text] [Related]
5. Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other beta-lactams.
Spangler SK; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1997 Feb; 39(2):141-8. PubMed ID: 9069533
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to cefditoren, and provisional interpretive criteria.
Fuchs PC; Barry AL; Brown SD
Diagn Microbiol Infect Dis; 2000 Aug; 37(4):265-9. PubMed ID: 10974578
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy.
Stefani S; Mezzatesta ML; Fadda G; Mattina R; Palù G; Rossano F; Tufano MA; Schito GC; Nicoletti G
J Chemother; 2008 Oct; 20(5):561-9. PubMed ID: 19028617
[TBL] [Abstract][Full Text] [Related]
9. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media.
Fenoll A; Aguilar L; Robledo O; Giménez MJ; Tarragó D; Granizo JJ; Gimeno M; Coronel P
J Antimicrob Chemother; 2007 Aug; 60(2):323-7. PubMed ID: 17562681
[TBL] [Abstract][Full Text] [Related]
10. [Cefditoren and community-acquired lower respiratory tract infections (corrected)].
Barberán J; Mensa J
Rev Esp Quimioter; 2009 Sep; 22(3):144-50. PubMed ID: 19662548
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
Johnson DM; Biedenbach DJ; Beach ML; Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 2000 Jun; 37(2):99-105. PubMed ID: 10863104
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on cefditoren.
Tempera G; Furneri PM; Carlone NA; Cocuzza C; Rigoli R; Musumeci R; Pilloni AP; Prenna M; Tufano MA; Tullio V; Vitali LA; Nicoletti G
J Chemother; 2010 Jun; 22(3):153-9. PubMed ID: 20566418
[TBL] [Abstract][Full Text] [Related]
13. Update of the activity of cefditoren and comparator oral beta-lactam agents tested against community-acquired Streptococcus pneumoniae isolates (USA, 2004-2006).
Fritsche TR; Biedenbach DJ; Jones RN
J Chemother; 2008 Apr; 20(2):170-4. PubMed ID: 18467241
[TBL] [Abstract][Full Text] [Related]
14. In vitro study of the post-antibiotic effect and the bactericidal activity of Cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens.
Dubois J; St-Pierre C
Diagn Microbiol Infect Dis; 2000 Jul; 37(3):187-93. PubMed ID: 10904192
[TBL] [Abstract][Full Text] [Related]
15. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.
Thornsberry C; Jones ME; Hickey ML; Mauriz Y; Kahn J; Sahm DF
J Antimicrob Chemother; 1999 Dec; 44(6):749-59. PubMed ID: 10590275
[TBL] [Abstract][Full Text] [Related]
16. influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene.
Torrico M; Aguilar L; González N; Giménez MJ; Echeverría O; Cafini F; Sevillano D; Alou L; Coronel P; Prieto J
Antimicrob Agents Chemother; 2007 Oct; 51(10):3699-706. PubMed ID: 17664320
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren.
Karlowsky JA; Jones ME; Draghi DC; Critchley IA; Thornsberry C; Sahm DF
Diagn Microbiol Infect Dis; 2002 Jan; 42(1):59-64. PubMed ID: 11821173
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of cefditoren against a special collection of clinical isolates of Streptococcus pneumoniae from Hungary.
Nagy E; Marton A; Hajdú E
Acta Microbiol Immunol Hung; 2003; 50(2-3):119-24. PubMed ID: 12894483
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States.
Biedenbach DJ; Jones RN; Fritsche TR
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):240-4. PubMed ID: 18353594
[TBL] [Abstract][Full Text] [Related]
20. Are beta-lactam breakpoints adequate to define non-susceptibility for all Haemophilus influenzae resistance phenotypes from a pharmacodynamic point of view?
Alou L; Giménez MJ; Sevillano D; Aguilar L; González N; Echeverría O; Torrico M; Coronel P; Prieto J
J Antimicrob Chemother; 2007 Apr; 59(4):652-7. PubMed ID: 17341471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
